Literature DB >> 3023627

Control of Rous sarcoma virus RNA translation and packaging by the 5' and 3' untranslated sequences.

J L Darlix.   

Abstract

A cytopathic mutant of Rous sarcoma virus-PrB was isolated and shown to have two large deletions, which result in the junction of Gag sequences in P27 to the 5' end of Env, and in the loss of the Src gene. This replication-defective (rd) and transformation-defective (td) mutant can replicate in the presence of its helper, which is also td, but the viral particles produced are poorly infectious. Most of the virions do not contain viral RNA, and the mutant RNA accumulates in infected cells, where it is poorly translated and packaged. Molecular clones of the mutant, of its helper and of a PrBtd strain were obtained in lambda-EMBL3, characterized, shown to be biologically active by transfection assays and sequenced. Nucleotide sequence comparisons indicate that the strong ribosome-binding site of Rous sarcoma virus RNA, responsible for the efficient RNA translation in vivo and in vitro, is mutated in PrB-(HM) mutant RNA; this causes the inhibition of RNA translation, as demonstrated by translation competition experiments using virus RNA made in vitro that carries the original or the mutated ribosome-binding site. In addition, an insertion present at the 3' end of both the mutant and the helper RNA, but absent in PrBtd RNA, is probably responsible for the inhibition of RNA packaging. Finally, these data are discussed in the light of a model of a 5'----3' Rous sarcoma virus RNA structure leading to a circular RNA molecule, which has implications in RNA translation, packaging and reverse transcription.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023627     DOI: 10.1016/0022-2836(86)90314-1

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  21 in total

1.  A mutation in the short 5'-proximal open reading frame on Rous sarcoma virus RNA alters virus production.

Authors:  R B Petersen; A Moustakas; P B Hackett
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Complete nucleotide sequence of a highly infectious avian leukosis virus.

Authors:  E Bieth; J L Darlix
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

3.  Circularization of the HIV-1 genome facilitates strand transfer during reverse transcription.

Authors:  Nancy Beerens; Jørgen Kjems
Journal:  RNA       Date:  2010-04-29       Impact factor: 4.942

4.  Phylogenetic and physical analysis of the 5' leader RNA sequences of avian retroviruses.

Authors:  P B Hackett; M W Dalton; D P Johnson; R B Petersen
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

5.  Alterations of the three short open reading frames in the Rous sarcoma virus leader RNA modulate viral replication and gene expression.

Authors:  A Moustakas; T S Sonstegard; P B Hackett
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  A study of the dimer formation of Rous sarcoma virus RNA and of its effect on viral protein synthesis in vitro.

Authors:  E Bieth; C Gabus; J L Darlix
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

7.  Effects of alterations in the leader sequence of Rous sarcoma virus RNA on initiation of translation.

Authors:  C H Hensel; R B Petersen; P B Hackett
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Generation of a helper cell line for packaging avian leukosis virus-based vectors.

Authors:  P Savatier; C Bagnis; P Thoraval; D Poncet; M Belakebi; F Mallet; C Legras; F L Cosset; J L Thomas; Y Chebloune
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 9.  Requirements for efficient minus strand strong-stop DNA transfer in human immunodeficiency virus 1.

Authors:  Dorota Piekna-Przybylska; Robert A Bambara
Journal:  RNA Biol       Date:  2011-03-01       Impact factor: 4.652

10.  The LTR, v-src, LTR provirus generated in the mammalian genome by src mRNA reverse transcription and integration.

Authors:  J Bodor; J Svoboda
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.